PDL Focus Remains Nuvion, But 2007 Could Include Several Significant Deals
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech is “aggressively” seeking potential in-licensing opportunities and hopes to partner its heart failure agent ularitide in 2007.
You may also be interested in...
PDL Advances Ulcerative Colitis Treatment Nuvion Into Phase III
Firm is still considering a potential partner for the monoclonal antibody.
PDL Advances Ulcerative Colitis Treatment Nuvion Into Phase III
Firm is still considering a potential partner for the monoclonal antibody.
PDL BioPharma Seeks Ularitide Partner That Grants Rights To A Late-Stage Drug
A more complicated partnership involving two clinical programs is taking more time to complete than a “ularitide-only” deal, the biotech says.